ImClone Systems

ImClone Systems is a biotechnology company known for developing cancer treatments, particularly focused on monoclonal antibody therapies. Their most notable product is Erbitux (cetuximab), which targets specific cancer cells, especially in colorectal and head and neck cancers. The company emphasizes innovative research to improve cancer care and enhance patient outcomes. Initially founded in 1984, ImClone gained significant attention after facing various challenges, including regulatory hurdles and legal issues. It was acquired by Eli Lilly and Company in 2008, allowing for broader integration of its therapies within larger healthcare systems.